Listed by the USPTO as MEYERING, SHABANA SHABBEER
Tech Center 4100 • Art Units: 1600 1635 1636 1654 4100
This examiner grants 68% of resolved cases
MEYERING, SHABANA SHABBEER is assigned to tech center 4100 and art unit 1600. The profile records 73 resolved cases and a 68.5% allowance rate. The interview lift is 45.1%, showing a meaningful positive association with allowance outcomes. The median time to allowance is 1124 days.
The listed companies are University of Massachusetts, Regeneron Pharmaceuticals Inc., and Centre National de la Recherche Scientifique. The listed firms are Clark+Elbing LLP, ADE & COMPANY INC., and BAKER BOTTS L.L.P. The case volume is limited enough that practitioners should use the figures as directional rather than conclusive. The interview measure nevertheless supports active examiner engagement, while the allowance result indicates that applicants should pair that engagement with careful written claim positioning and realistic timing assumptions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17428722 | CORE MASTER REGULATORS OF GLIOBLASTOMA STEM CELLS | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18561036 | APPARATUS AND METHOD FOR CONTINUOUS PRODUCTION OF RNA | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 18141166 | PROTECTING OLIGONUCLEOTIDES FOR CRISPR GUIDE RNA | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17810022 | METHODS FOR THE TREATMENT OF EPILEPSY | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17597351 | METHODS FOR THE TREATMENT OF EPILEPSY | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18467442 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | Final Rejection | UNIVERSITY OF ROCHESTER |
| 18884527 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17312260 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | Final Rejection | Yale University |
| 18214333 | Nucleic Acids That Manipulate Immune Pathways | Non-Final OA | Children`s Medical Center Corporation |
| 18120204 | MICRORNA INHIBITOR SYSTEM AND METHODS OF USE THEREOF | Non-Final OA | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 18294577 | HYBRID PROMOTERS FOR GENE EXPRESSION IN MUSCLES AND IN THE CNS | Final Rejection | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.5% of resolved applications examined by Shabana Shabbeer Meyering were allowed (73 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +45.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Shabana Shabbeer Meyering took 1,124 days on average from filing to allowance.
Shabana Shabbeer Meyering examines applications in Art Unit 1600 in Tech Center 4100.
